RemeGen Co., Ltd. Issues Supplemental Announcement on Wealth Management Products Purchases and Listing Rules Compliance
Key Points for Investors
- Delayed Disclosure: RemeGen Co., Ltd. (Stock Code: 9995) has admitted to delayed reporting of multiple wealth management product purchases, which constitutes a breach of Hong Kong Listing Rules.
- Aggregate Transactions: Between April 28, 2026 and May 13, 2026, the company purchased seven wealth management products from the same bank, which must be aggregated for disclosure purposes under Rule 14.22.
- Discloseable Transaction Triggered: On April 30, 2026, the aggregated percentage ratios for these purchases exceeded 5% (but were less than 25%), thus triggering a discloseable transaction under Chapter 14.
- Failure to Timely Report: The company should have reported these transactions on several dates (April 30, May 6, May 11, and May 13, 2026) but failed to do so due to inadvertent oversight.
- Remedial Measures: RemeGen has outlined detailed remedial measures to prevent future non-compliance, including enhanced internal controls, regular training, and consulting external advisors.
Details of the Announcement
RemeGen Co., Ltd., a PRC-based pharmaceutical company, has issued a supplemental announcement regarding its purchase of wealth management products under agreements with SPD Bank. The purchases, made between April 28 and May 13, 2026, were not properly disclosed as required under Hong Kong’s Listing Rules. This oversight is significant as it demonstrates a lapse in internal compliance controls and could impact investor confidence.
Transaction Aggregation and Disclosure Requirements
The company purchased seven wealth management products from the same financial institution within a 12-month period. According to Rule 14.22, such transactions must be aggregated for the purposes of calculating the relevant percentage ratios. On April 30, 2026, the aggregated ratio exceeded the 5% threshold, triggering the requirement to publicly disclose the transaction as a “discloseable transaction” under Chapter 14. However, the company failed to make timely announcements on the required dates due to oversight.
Impact on Shareholders and Potential Price Sensitivity
- Compliance Breach: The company’s delayed reporting of transactions may raise concerns among shareholders regarding RemeGen’s governance and internal controls. Such delays could affect investor sentiment and potentially impact share price, especially given the importance of transparency in the Hong Kong market.
- Remedial Actions: The company has committed to several corrective steps:
- Issuing internal memos to directors and relevant departments emphasizing strict compliance with Listing Rules.
- Enhancing its wealth management product control list, with regular updates and monitoring of subscription/redemption dates, transaction amounts, interest earned, and outstanding balances both individually and in aggregate.
- Strengthening inter-departmental communication and coordination, with the finance department reviewing and verifying all relevant details and regulatory implications before any potential notifiable transaction is executed.
- Regular internal training sessions for directors and relevant staff, provided by legal and professional advisors, to reinforce understanding of disclosure obligations.
- Consulting external advisors and the Stock Exchange as necessary before entering any notifiable transactions.
- Commitment to Compliance: RemeGen states it will timely comply with reporting obligations for future transactions, aiming to restore confidence among shareholders and regulatory authorities.
Board Composition
As of May 19, 2026, the board consists of a mix of executive, non-executive, and independent directors, led by Chairman Mr. Wang Weidong. This diversified board is expected to oversee the implementation of remedial measures and ensure future compliance.
Conclusion
This announcement is highly relevant for investors and shareholders as it reveals a compliance breach that could have regulatory and reputational consequences for RemeGen. The company’s swift remedial actions and commitment to transparency are positive signs, but the incident may still affect investor confidence and share price in the short term.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making any investment decisions. The information is based on company announcements and may be subject to change.
RemeGen 補充公告：購買理財產品及上市規則合規詳情（廣東話版）
投資者需注意的重點
- 延遲披露：RemeGen（股份代號：9995）承認延遲披露多項理財產品購買，構成香港上市規則違規。
- 交易需合併計算：公司於2026年4月28日至5月13日期間，於同一銀行購買七款理財產品，根據《上市規則》第14.22條需合併計算披露比例。
- 觸發須披露交易：2026年4月30日，合併計算後的比例超過5%（但少於25%），觸發需披露交易，但公司因疏忽未能及時公告。
- 合規措施：公司已提出多項補救措施，包括加強內部監控、定期培訓及諮詢外部專業顧問。
公告詳細內容
RemeGen發出補充公告，指其於SPD銀行協議下購買理財產品時，未能按香港上市規則及時披露，屬重大合規問題。此舉反映公司內部管控出現漏洞，或影響投資者信心。
交易合併及披露要求
公司於12個月內向同一金融機構購買七項理財產品，需合併計算比例。2026年4月30日，合併後比例超過5%，觸發《上市規則》第14章須披露交易，惟公司未能按要求於相關日期公告。
對股東及股價的潛在影響
- 合規違規：延遲披露或令股東憂慮公司治理及內部監控，影響投資者信心，短期內或影響股價。
- 補救措施：公司承諾：
- 向董事及部門發內部通告，強調嚴格遵守上市規則。
- 強化理財產品監控清單，定期更新交易及餘額。
- 加強部門協作，財務部審核監控所有交易細節及規則要求。
- 定期由法律及專業顧問為董事及員工提供內部培訓。
- 如有需要，諮詢外部專業顧問及聯絡聯交所。
- 合規承諾：公司將嚴格遵守披露要求，力求恢復投資者及監管機構信心。
董事會組成
截至2026年5月19日，董事會包括執行、非執行及獨立董事，由主席王衛東領導，預期可監督補救措施落實及確保未來合規。
總結
此公告對投資者極為重要，揭示公司合規失誤，可能帶來監管及聲譽風險。公司迅速補救及承諾透明，有助恢復信心，但短期內或影響股價。
免責聲明
本文僅供參考，不構成投資建議。投資者應自行研究及諮詢專業顧問作出投資決策，內容以公司公告為依據，可能隨時變動。
